Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for Leap Therapeutics, Inc. under the historical ticker LPTX provides official documentation of the company’s evolution into Cypherpunk Technologies Inc. and its dual focus on oncology therapeutics and a Zcash-centered digital asset treasury strategy. Forms 8-K detail key events such as the October 2025 private placement led by Winklevoss Capital, adoption of the digital asset treasury strategy, and subsequent name change to Cypherpunk Technologies Inc., along with the planned shift to trading under the symbol CYPH on the Nasdaq Capital Market.
Regulatory reports describe capital markets transactions, including the issuance of common stock, pre-funded warrants, and common warrants, registration rights agreements, and a controlled equity offering sales agreement that allows at-the-market issuances of common stock. Other filings outline Nasdaq bid price deficiency notices, the grant of an additional compliance period, and the company’s consideration of a reverse stock split to address listing standards.
Filings also cover corporate governance and compensation, such as consulting and employment agreements with new digital asset–focused leadership, equity incentive awards in the form of restricted stock units, and board expansion and nomination rights for the lead investor. The definitive proxy statement for a special meeting explains proposals to increase authorized shares, authorize a reverse stock split range, adopt a new equity incentive plan, and approve additional share issuance under the private placement warrants.
For those analyzing the oncology side of the business, 8-Ks and related exhibits reference the wind-down of the DeFianCe clinical trial, reductions in research and development activities, and the exploration of strategic alternatives for sirexatamab and FL-501. On Stock Titan, these filings are paired with AI-powered summaries that help interpret complex agreements, capital structure changes, and disclosure language, while real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, and proxy materials for the issuer formerly known as Leap Therapeutics are quickly accessible.
CYPHERPUNK TECHNOLOGIES INC. director Christopher Mirabelli reported an open-market sale of 60,000 shares of Common Stock at an average price of $0.7105 per share on March 26, 2026. According to the footnote, the sale was made to cover estimated taxes related to a previously reported settlement of RSUs on March 13, 2026. After this transaction, Mirabelli directly owns 130,376 shares of the company’s common stock.
Cypherpunk Technologies Inc. director Dietz Thomas John exercised previously granted equity awards and increased his direct common share holdings. On March 13, 2026, 104,500 Restricted Stock Units granted on December 23, 2025 under the 2025 Equity Incentive Plan were settled on a 1-for-1 basis into 104,500 shares of common stock for no cash consideration. These RSUs had vested at issuance. Following the settlement, he directly holds 152,500 shares of Cypherpunk Technologies common stock and no remaining RSU position from this grant.
Cypherpunk Technologies Inc. director Christopher Mirabelli exercised restricted stock units into common shares as part of his equity compensation. On March 13, 2026, he settled 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 on a 1-for-1 basis into common stock at $0.00 per share. Both RSU grants had vested at issuance. Following these conversions, he directly holds 190,376 shares of common stock and has no remaining derivative positions from these RSUs.
Cypherpunk Technologies Inc. director Oei Khing Djien increased his direct holdings through the settlement of previously granted restricted stock units. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were settled 1-for-1 into common shares for no cash consideration. Both RSU grants had vested at issuance. Following these derivative exercises/conversions, he directly holds 168,750 shares of common stock.
Cypherpunk Technologies Inc. director William Li acquired shares through the settlement of previously granted restricted stock units. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were settled on a 1-for-1 basis into common stock for no cash consideration.
These RSUs vested at issuance on their grant dates and were granted under the company’s 2022 and 2025 equity incentive plans. Following the settlements, Li directly holds 168,750 shares of common stock, and no RSU derivatives from these grants remain outstanding.
Cypherpunk Technologies Inc. director Richard Christian M acquired common shares through the settlement of previously granted restricted stock units. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled 1-for-1 into common stock for no cash consideration. Following these compensation-related conversions, he directly holds 168,750 shares of common stock, with no remaining RSUs reported in this filing and no open-market purchases or sales disclosed.
Cypherpunk Technologies Inc. director Mashiach Nissim settled previously granted stock awards into common shares. On March 13, 2026, Nissim exercised and settled 74,700 restricted stock units granted in November 2025 and 94,050 restricted stock units granted in December 2025 on a 1-for-1 basis into the same number of shares of common stock, for no cash consideration. These RSU grants had vested at issuance, and following the settlements Nissim directly owns 168,750 shares of Cypherpunk Technologies common stock. The filing shows no share sales or tax-withholding dispositions associated with these transactions, indicating a net increase in his equity stake.
Cypherpunk Technologies Inc. director Patricia A. Martin reported the settlement of previously granted restricted stock units into common shares. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were exchanged on a 1-for-1 basis for common stock at no cash cost.
These RSUs were granted under the company’s 2022 and 2025 equity incentive plans and vested at issuance on their respective grant dates. Following these settlements and related derivative exercises, Martin directly holds 168,750 shares of Cypherpunk common stock, with no remaining RSUs shown in this filing.
Schilsky Richard reported acquisition or exercise transactions in this Form 4 filing.
Cypherpunk Technologies director Richard Schilsky increased his equity stake through RSU settlements, not open-market buying. On March 13, 2026, 74,700 Restricted Stock Units granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled 1-for-1 into common shares for no cash consideration. Both RSU awards had vested at issuance. Following these conversions, Schilsky directly holds 168,750 shares of Cypherpunk Technologies common stock as reported in the filing.